EverPoint Asset Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

EverPoint Asset Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-300,000	Closed	-$4.43M	–	568
2016 Q3	$4.43M	Buy	300,000 +84,000	+39%	+$967K	0.08%	264
2016 Q2	$1.94M	Buy	216,000 +65,471	+43%	+$680K	0.04%	324
2016 Q1	$1.39M	Sell	150,529 -199,471	-57%	-$1.68M	0.03%	364
2015 Q4	$4.41M	Hold	350,000	–	–	0.09%	268
2015 Q3	$4.56M	Buy	350,000 +50,000	+17%	+$919K	0.12%	227
2015 Q2	$6.55M	Buy	+300,000	New	+$6.84M	0.12%	237

Other funds holding TRIL

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

IBT

International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

EverPoint Asset Management's TRIL Position: Q4 2016 in Review

EverPoint Asset Management sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2016, closing a stake of 300,000 shares — an estimated $4.43M sold.

EverPoint Asset Management first reported a position in TRIL in Q2 2015 and held it in 6 quarters. The position peaked at $6.55M in Q2 2015. 29 funds tracked by Wall St. Rank hold TRIL as of Q4 2016.

EverPoint Asset Management reported no remaining Trillium Therapeutics Inc. position as of Q4 2016 after selling out during the quarter.
EverPoint Asset Management sold 300,000 Trillium Therapeutics Inc. shares in Q4 2016, an estimated $4.43M.
EverPoint Asset Management first reported a position in Trillium Therapeutics Inc. in Q2 2015 and held it in 6 quarters.
EverPoint Asset Management's Trillium Therapeutics Inc. position peaked at $6.55M in Q2 2015.
29 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.